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Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention
of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific
community needed to express recommendations on the human use of resveratrol. Such recommendations were
formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group
stated that the evidence was “not sufficiently strong to justify recommendation for the chronic administration of
resveratrol to human beings, beyond the dose which can be obtained from dietary sources.” It was a disappointing
conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However,
since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging
results, it is necessary to formulate updated versions of the recommendations.
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Introduction
Resveratrol is a naturally occurring stilbene, collo-
quially known as “red wine medicine.” Resveratrol is
a chemically simple compound, but various resver-
atrol derivatives, as well as dimeric, trimeric, and
tetrameric forms, are found in nature. Although re-
cent studies have explored these resveratrol deriva-
tives, the present review is focusing on resveratrol
only.
Resveratrol has received much attention in pub-
lic and scientific communities, and a set of recom-
mendations in relation to human consumption was
formulated at Resveratrol2010, the 1st International
Conference on Resveratrol and Health (Helsingør,
Denmark). The aim of the present review is to show
the relevance of these recommendations in 2010 and
to discuss the necessity of formulating a new set of
recommendations at the Resveratrol2012 meeting
in Leicester, December 2012.
When Takaoka first published the existence of
resveratrol in Veratrum grandiflorum,1 very few no-
ticed this observation, until some biological effects
observed from extracts of Polygonum cuspidatum
were linked to its high content of resveratrol2 and
resveratrol was found in edible sources such as
grapes and wine.3 The major findings of biological
responses to resveratrol (Fig. 1) can be characterized
as (1) Frankel et al. found in 1993 that resveratrol
modulates LDL levels, indicating a potential reduced
risk for development of coronary heart disease;4
(2) the chemo-preventive effect of reseveratrol in a
mouse skin cancer model was shown by Jang et al.5
in 1997; (3) a major focus was prompted by the
observation that resveratrol extends the life span of
yeast;6 (4) the effect of resveratrol on obesity and
diabetes was identified by two groups in 2006.7,8 A
few phase I clinical trials focusing on the pharma-
cokinetics of resveratrol were published before 2010,
but since then, the number of clinical trials explor-
ing the biological effects of resveratrol has increased
significantly.
Scientific focus on resveratrol
The scientific focus on resveratrol has followed
the profile of curcumin and, to a lesser extent
quercetin (Fig. 1), whereas several other naturally
doi: 10.1111/nyas.12173
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Figure 1. Increasing scientific interest on the biological effects of resveratrol and other naturally occurring bioactive sub-
stances. The number of hits obtained by searching (A) “resveratrol” and (B) “curcumin,” “indole-3-carbinol,” “genistein,”
“quercetin,” or “epigallocatechin-3-gallate” (EGCG) for each year from 1980 to 2012 on PubMed (http://www.ncbi.nlm.nih.gov/
pubmed?db=pubmed) is shown.
occurring bioactive substances, such as indole-3-
carbinol (from cruciferous vegetables) or genistein
(mainly from soybeans) have shown quite differ-
ent profiles of interest. The chemopreventive effect
of indole-3-carbinol was proposed in animal mod-
els in 1978 by Wattenberg et al.,9 but the annual
number of scientific publications has been quite
constant over the years. The scientific interest in
the flavonoid quercetin was also significant in the
1980s and 1990s, with an increased interest during
the first decade of 2000. Comparisons of publica-
tion frequency indicate a more specific increased
scientific interest in resveratrol and curcumin rel-
ative to many other potentially health-promoting
naturally occurring compounds. Further, the inter-
est for resveratrol and curcumin has not yet reached
a plateau, as observed for genistein.
The total number of scientific publications in-
dexed in PubMed has increased in the period ana-
lyzed (from about 280,000 in 1980 to about 910,000
in 2012). Even when taking this total increase of
publications into consideration, the increase in
publications focusing on resveratrol or cur-
cumin is very significant. The scientific focus on
2
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Figure 2. Relative search activity on the Internet using Google. The search activity is displayed by using Google Trends (http://
www.google.com/trends/explore) in the period of January 2004–December 2012. The search words were “resveratrol,” “curcumin,”
“genistein,” and “quercetin.”
resveratrol is high relative to other naturally oc-
curring compounds. By December 2012, the ac-
cumulated number of PubMed-identified publica-
tions focused on resveratrol was comparable with
curcumin (both around 5400 publications), nearly
half as many as genistein or quercetin (both around
9600 publications), and significantly more than
well-known bioactive compounds like apigenin,
epigallocatechin-3-gallate, lycopene, ellagic acid,
naringin, sulforaphane, and dialylsulfide (ranging
between 300 and 3000 publications).
Resveratrol claims
Nearly all data concerning the biological effects of
resveratrol up to 2010 were generated in vitro or in
animal models. Therefore, the health significance
of resveratrol in humans has been unclear, even
though the substance has been popularly claimed
as a treatment agent for a range of cancers and
as an antiaging compound. Such claims are not
supported by strong scientific evidence. Translat-
ing specific scientific messages from experimental
laboratories to the general public is a very difficult
and complex task. It is in general a major challenge
that most of the statements concerning the health
effects of resveratrol are based on animal studies and
mechanistic studies (in vitro), and details relevant
to experimental setup and models are often lost in
translation from the scientific literature to the mass
media.
In addition, there are a number of examples where
the outcome from in vitro experiments differs from
the response in experimental animals or from the
effects observed in humans. As one recent example,
resveratrol inhibited cell proliferation and invasive-
ness of ovarian cancer cells in vitro, but did not
exhibit this effect on the same cancer cells in vivo.10
Therefore, one has to be careful when translating
data from in vitro experiments or animal experi-
ments to humans. On the other hand, as will be
discussed later, the options for performing the op-
timal or correct experiments in humans to prove
the effect of substances like resveratrol are rather
limited.
The focus on resveratrol in the public
domain
Scanning Internet search activities can provide a
relevant parameter of interest in the public do-
main. A search using Google Trends (http://www.
google.com/trends/) provides the relative search ac-
tivities using Google search machinery since 2004
(Fig. 2). In the public domain as well as in the sci-
entific community, there is a large interest for in-
formation on resveratrol, which peaked in late 2006
and during 2009. The peak in interest in 2006 can
be related to the scientific breakthroughs that year
by Baur et al.7 and Lagouge et al.,8 whereas the peak
in 2009 was likely because of a high public focus on
resveratrol by trendsetters like Oprah Winfrey. The
interest has, since 2009, generally been at a much
higher level compared to curcumin, genistein, or
quercetin. In the same time period, the number of
websites dedicated to resveratrol has increased ex-
ponentially, with significantly more sites focusing
on resveratrol than curcumin.
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Overall conclusions from the working
group at Resveratrol 2010
By 2010, in light of the increasingly large number of
publications, the growing hype around resveratrol,
and the large number of unsupported claims about
its health benefits propagated by the media, there
was a need to sum up all the available scientific
data on resveratrol and to formulate recommen-
dations for the human use of resveratrol and for
research in the coming years. As a follow-up from
Resveratrol2010, the 1st International Conference
on Resveratrol and Health (Helsingør, Denmark),
such recommendations were formulated and pub-
lished in PLoS One in 2011.11 By considering the
knowledge gained as a result of the formulation of
these recommendations, we can evaluate their sig-
nificance and consider whether the recommenda-
tions need to be updated.
The overall conclusion from the Resveratrol2010
working group was presented as a double statement:
“The published evidence is not sufficiently strong
to justify a recommendation for the administration
of resveratrol to humans, beyond the dose which
can be obtained from dietary sources,” but “ani-
mal data are promising in prevention of various
cancer types, coronary heart diseases, and diabetes,
which strongly indicate the need for human clinical
trials.”11 The major challenge at the time of formu-
lation of the recommendations was that no human
clinical trials were available, even though a few were
published in the few months after the conference.
On the basis of the animal data alone, the work-
ing group could not support recommendations for
resveratrol use in humans at higher concentrations
than those obtained through the diet. The transla-
tion from animal to human is not straightforward
because of potential differences between experimen-
tal animals (rodents) and humans in the bioavail-
ability and mechanisms of action of resveratrol. A
careful statement was chosen, which was supported
by the animal experiments completed and published
at that time.
The evaluation was based on the following five
test questions:11
1. Can resveratrol be recommended in the pre-
vention or treatment of human diseases?
2. Are there observed side effects caused by the
intake of resveratrol in humans?
3. What is the relevant dose of resveratrol?
4. What valid data are available regarding an
effect in various species of experimental
animals?
5. Which relevant (overall) mechanisms of ac-
tion of resveratrol have been documented?
Questions 1–3 focus on the effects of resvera-
trol in humans, whereas question 4 concerns the
effects of resveratrol in animal models. The first
part of the overall conclusion addressed 1–3, stating
that administration of extended levels of resveratrol
to humans cannot be recommended. As long-term
exposure trials with resveratrol had not been per-
formed at that time; there were neither direct data
on side effects nor data from humans that could
support an estimated dose of resveratrol for human
use. No-observed-adverse-effect levels for maternal
toxicity and embryo–fetal development are around
750 mg resveratrol/kg/day in rats, which has been
translated to a safe daily dose of 450 mg for a 60 kg
person.12 This estimate was based on one long-term
study in one species and a study in a second species
is necessary.
Although the working group could not recom-
mend a specific dose of resveratrol for human intake
because health-promoting effects had not been in-
vestigated in humans, it was also necessary to state
that no significant side effects have been observed
in animal studies or in short-term human studies
when very high doses of resveratrol were used (e.g.,
2.5–5 g/day).
Advantages and challenges of the
recommendations
These formal recommendations on the human use
of resveratrol summarize the existing body of knowl-
edge in a few lines, assuming that the members of the
working group have done their best to compile the
most valid data in the recommendations. The con-
clusions may be used directly by medical doctors to
address questions from their patients about whether
dietary supplementation with resveratrol may pre-
vent lifestyle diseases. The recommendations may
be used also by a well-oriented layperson, relevant
target person, or member of the media who needs
a source for presenting valid scientific information
on resveratrol. The recommendations also provide
goals for the future of research needed in the field
of resveratrol to answer the question of human use.
4
Ann. N.Y. Acad. Sci. 1290 (2013) 1–11 C© 2013 New York Academy of Sciences.
Vang Resveratrol recommendation
On the other hand, such short brief statements
may well be too simple to express the nuances rel-
evant to the diversity of biological effects of resver-
atrol. Resveratrol seems to have numerous cellu-
lar targets. Not all of these targets are likely to be
equally relevant to any one disease. Problems rel-
evant to issues like resveratrol administration may
also be masked by such brevity. In the attempt to
make clear recommendations, the working group
may have made the same error of oversimplifica-
tion of which we accuse the media in relation to the
effects of resveratrol.
How was the message received in the
scientific and general societies?
Scientific relevance can be measured by the number
of citations of the publication in PLoS One.11 Using
the metric analysis at the PLoS One article homepage
(http://www.plosone.org/article/info%3Adoi%2F
10.1371%2Fjournal.pone.0019881), where the
paper was ranked among the top five resveratrol
papers published in PLoS One (December 2012) in
relation to number of citations and the usage of
the article (number of downloads), 11/2 years after
publication. In contrast, the recommendations
have only rarely been cited on the Internet outside
of scientific publications. However, claims found
on the Internet in relation to the health effects
of resveratrol appear to be much more balanced
at present, indicating that the formulation of the
recommendations has had an effect on the delivery
of the information on resveratrol.
Clinical trials testing the health-promoting
effect of resveratrol: what has happened
since September 2010?
One of the central recommendations from the work-
ing group at the Resveratrol2010 conference was to
initiate clinical trials to evaluate the health effects
of resveratrol in humans, and many such trials have
been published since September 2010. Table 1 lists
the published trials up to the end of 2012 testing the
effect of pure resveratrol, whereas Table 2 lists trials
of resveratrol as part of a mixture with other poten-
tially bioactive compounds. Translating the effects
of resveratrol from studies using a mixture contain-
ing resveratrol is not possible without data from ex-
periments where resveratrol is used in a pure form.
On the other hand, exclusively evaluating trials with
pure resveratrol will not reveal relevant combina-
tory effects of resveratrol with other bioactive com-
pounds.
The specific doses of resveratrol used in the var-
ious experiments differ dramatically. Using pure
resveratrol, daily doses as low as 5 mg twice daily for
four weeks showed an effect on insulin sensitivity,13
and 10 mg/day for three months produced increased
flow-mediated dilation.14 Daily doses up to 2.5 or
5 g resveratrol have been used in several trials for up
to 29 days with effects on the relevant biochemical
parameters.15,16 Adverse effects have been observed
using such high resveratrol levels: therefore the daily
dose during long-term exposure to pure resveratrol
should be kept below 1–1.5 g.
Both sexes have been included in the trials. Only a
few trials have included young healthy subjects,17 as
most trials have focused on subjects with a disease
or increased risk for the development of the disease.
Designing trials using subjects with pre-disease sta-
tus introduces difficulties in demonstrating preven-
tive effects, as several disease stages may have already
initiated even though the disease is not manifest.
Therefore, long-term clinical trials including young
subjects will need to be performed to assess pre-
ventive effects, but it will be challenging to demon-
strate relevant effects of resveratrol in such low-risk
cohorts.
The duration of the trials varies from acute
exposure,18,19 to a few days (5–8) of exposure,20,21
to up to one year.22 Most trials expose the subjects
to resveratrol in time frames of 1–3 months. The
relatively short duration of the trials is a challenge,
as they permit analysis of therapeutic but not pre-
ventive potential. Without taking the practical and
economical aspects of such studies into considera-
tion, a trial to show a preventive effect of resveratrol
should run for a minimum of one year. It is ob-
vious that such trials are expensive and not easily
funded, but they will be necessary to obtain rele-
vant information about the preventive potential of
resveratrol.
Most of the clinical trials, particularly the larger
ones, have focused on the effects of resveratrol on
cardiovascular disease and diabetes and on inflam-
mation status. The strongest effects were observed
in subjects with enhanced levels of disease-related
markers,13,14,19,23–25 but some trials did not show
any effect of resveratrol,26 even though study par-
ticipants had high-risk profiles.27 Trials examining
resveratrol in relation to cancer have been small in
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Table 1. Clinical trials analyzing biological effects of resveratrol. The biological effects of resveratrol (Resv) alone
have been studied in the trials shown in the table. The various effects are divided into groups depending on the major
scope of the trial





250 or 500 mg Resv
in a single dose





Open-label study 0.5 or 1.0 g daily
doses of Resv for
8 days
Tumor cell proliferation ↓ 21





42: 31 ♀, 11 ♂ Open-label study 1 g Resv/day for
4 weeks
Level of specific cytochrome P450
enzymes ↓
28
GST activity and GST- →






5 g Resv/day for
10–21 days
Hepatic apoptosis ↑ 16
Metabolic syndrome/insulin sensitivity/NAFLD/diabetes
11 overweight ♂ Randomized,
double-blinded
crossover study
150 mg Resv/day in
30 days
Sleeping and metabolic rate ↓





Systolic blood press. ↓
Lipolysis in adipose tissue ↓
Plasma fatty acids ↓







75 mg Resv/day for
12 weeks
Body composition →
Resting metabolic rate →
Plasma lipids →
Inflammatory markers →
Adipose tissue insulin sensitivity →
26









Endogenous glucose production →
Turnover and oxidation rates of
glucose →
No effect on blood pressure →
Resting energy expenditure →
Oxidation rates of lipid →
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Table 1. Continued
Number of subjects Type of study Dose and duration Effect of Resv Reference















Daily dose of 1, 1.5,
or 2 g Resv for
4 weeks
Peak post-meal glucose ↓



















A single acute dose





87 in three groups Randomized,
double-blinded,
active-controlled,








Quality of life ↑
Skin





10 g/g of gel.
Applied daily for
60 days
GAGS score: ↓ 29
GAGS, global acne grading system; GST, glutathione S-transferase; HDLc, high-density lipoprotein-cholesterol; IGF-I,
insulin-like growth factor-1; LDLc, low-density lipoprotein-cholesterol; ↑, increased response; ↓, decreased response;
→, no significant effect.
size and have focused on the therapeutic effect of
resveratrol in relation to cancer markers. Ironically,
such therapeutic studies have not really been per-
formed in experimental animals, where studies have
focused on the preventive effect of resveratrol.
To some extent, is it more meaningful to estimate
the effect of resveratrol when it is part of a dietary
matrix. It is likely also easier to get such trials ac-
cepted, as supplementations are more natural and
the exposure to resveratrol is generally lower in these
trials. Among the published trials where resveratrol
is part of a matrix, medium-high levels of resveratrol
have been used, but these have not shown statisti-
cally significant effects: in one trial, a 100–400 mg
resveratrol exposure reduced inflammation30 and
increased flow-mediated dilation,31 but these pa-
rameters were not found changed in other trials
using the same levels of resveratrol.20,31 However,
a set of trials where the subjects were exposed to
low amounts of resveratrol for six months and one
year did show significant effects on cardiovascular
biochemical markers.22,32
Beyond these major diseases, the effect of resver-
atrol on cognitive or brain function has been only
marginally investigated,17,18 while a significant effect
of resveratrol on skin was found in two studies.29,33
Do we need a new set of recommendations
for the use of resveratrol?
On the basis of the human trials focused on the
health-promoting effects of resveratrol conducted
during the last two years, the set of recommen-
dations formulated in September 2010 have to be
updated. The clinical trials are still small relative to
Ann. N.Y. Acad. Sci. 1290 (2013) 1–11 C© 2013 New York Academy of Sciences. 7
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Table 2. Clinical trials analyzing biological effects of resveratrol as part of a mix. The biological effects of resveratrol
(Resv) as part of a mixture have been studied in the trials shown in the table. The various effects are divided into the
major groups depending on the major scope of the trial
Number of subjects Type of study Dose and duration Effect of Resv Reference
Cognitive/brain function/emotional






Daily 46 g grape powder with
1.75 mg Resv/kg





Open-label study 3.9 or 15.6 mg/day Resv with
quercetin





Open-label study Freeze-dried grape powder
with Resv (corresponding
to 0.073 and 0.114 mg
Resv/day)
Wnt signaling in colon
cancer cells →
34
In normal cells ↓
12: 7 ♀, 5 ♂ Open-label study Food supplement containing
2 mg Resv + 100 mg grape
extract 3 times daily for
5 days





237 mL red or white wine for
21 days. The level of Resv is
not shown





30 healthy subjects Open-label study 1/3, 2/3, or 1 lb of red grapes
per day for 2 weeks, but the









extract containing 40 mg





10 subjects (31 ♀,







100 mg of Resv + 75 mg
polyphenols from a grape
extract/single
administration
TLR4 ↓, CD14 ↓,
SOCS3 ↓, IL-1 ↓,
Keap-1 ↓
Nrf-2 binding activity ↑,
expression of NQO-1 and
GST-P1 ↑
30
36 ♂, with BMI
between 25.5










Resv (25.2 mg/day for
5 weeks
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Table 2. Continued





Randomized 100 mg Resv (Longevinex R©)
daily for 0–3 or 3–6 months










1 capsule/day of 150 mg Resv,
400 mg catechin-rich grape
seed extract (CGSE), or







75 in 3 groups Triple-blinded
randomized
study
Placebo, 350 mg grape extract
(GE), 350 Resv-enriched
GE (8 mg Resv) for
6 months
LDLc ↓, ApoB ↓, oxLDL ↓ 32
oxLDL/ApoB; ↓
non-HDLc /ApoB ↑





Placebo, 350 mg grape extract
(GE), 350 Resv-enriched
GE (8 mg Resv) for
6 months + double
amount for next 6 months





Randomized 100 mg Resv (Longevinex)












272 mL red wine/day
(0.82 mg Resv) for 4 weeks
ICAM-1 ↓, E-selectin ↓, IL-6 ↓
Lymphocyte function-












133 mg grape extract (8 mg
Resv) /day for 60 days













Daily 46 g grape powder with
1.75 mg Resv/kg
(0.08 mg/day) for 45 days
VO2max → 17
Work capacity →
Perceived health status →
Inflammation →
Pain →
Physical function responses →
8-OH-dG, 8-deoxy-guanine; ApoB, apolipoprotein B; GSH, glutathione; GST, glutathion S-transferase; HDL, high
density lipoprotein; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; oxLDL, oxidized LDL; LDL, low density
lipoprotein; ROS, reactive oxygen species; TLR4, Toll-like receptor 4; SOCS3, suppressor of cytokine signaling 3; ↑,
increased response; ↓, decreased response; →, no significant effect.
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the sample sizes used for testing drugs, and analy-
sis of the possible disease-preventive effect is facing
several challenges. To determine potential preven-
tive effects of a dietary compound like resveratrol,
long-term exposures of large cohorts of participants
in stages of low risk of disease development are
needed. The dietary bioactive compounds do not
work like typically man-made drugs that have a sin-
gle high-affinity target, but rather modulate a range
of cellular targets with only low affinity. Therefore,
the effects of a single compound at low levels are
rather small, and one may expect that the biologi-
cal effects are caused by combined effects of several
(or many) dietary bioactive compounds ingested
simultaneously. Therefore, the effect of resveratrol
may be underestimated when analyzed as a single
compound under investigation.
Conclusions: what has been learned from
working with the recommendations?
Resveratrol has been the focus of considerable hype
in both the general and scientific communities. This
hype has propelled research on the compound, but it
has also stimulated the propagation of many unsup-
ported claims concerning the putative health ben-
efits of the compound. Therefore, it was necessary
in 2010 to formulate a set of recommendations on
the use of resveratrol. These have, in general, been
accepted well and have contributed to the establish-
ment of a series of clinical trials focusing on the
health effects of resveratrol. This high number of
clinical trials analyzing the effect of resveratrol de-
mand a new set of recommendations.
Most of these clinical trials have been designed to
evaluate the therapeutic effect of resveratrol rather
than the disease-preventive effect of the compound.
A preventive study needs to expose test subjects be-
fore they show any sign of the disease, and then
the cohort members have to be treated for a suffi-
ciently long time that a significant amount of sub-
jects in the control group will develop the disease.
To get substantial power in the analysis, the number
of participants has to be high. Therefore, these tri-
als will be very expensive, and the number of such
studies in the future will be low: other models for
prevention studies have to be included. The use of
the pig as a reliable model will support the preven-
tion experiments in rodents and provide us with
necessary knowledge that may not be available in
humans.
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